James McNulty

James McNulty

Direttore Finanziario/CFO presso HEDGEPATH PHARMACEUTICALS INC

Patrimonio netto: 176 646 $ in data 31/08/2026

76 anni
Health Technology
Commercial Services
Distribution Services

Profilo

James A. McNulty is the founder of Pender, McNulty & Newkirk, founded in 1976.
Mr. McNulty is also the founder of McNulty & Co.,McNulty, Garcia & Ortiz PA..
Mr. McNulty is Director-Tampa Bay Chapter at Financial Executives International since 2013.
Mr. McNulty is Independent Director at Lunai Bioworks, Inc. starting 2024.
Mr. McNulty is a Member of The American Institute of Certified Public Accountants.
Mr. McNulty is a Member of Florida Institute of Certified Public Accountants.
Mr. McNulty is Chief Financial Officer, Secretary & Treasurer at Inhibitor Therapeutics, Inc. since 2022.
Mr. McNulty is Chief Financial Officer at Repurposed Therapeutics, Inc. Mr. McNulty is Chief Financial Officer at MIRALOGX LLC.
Former positions include Chief Executive Officer at MyMD Pharmaceuticals (Florida), Inc. from 2014 to 2020.
Lead Independent Director at CV Sciences, Inc. from 2016 to 2020.
Director at Quantum Technology Sciences, Inc. Chief Financial Officer at Rock Creek Pharmaceuticals, Inc. from 1998 to 2000.
Treasurer & Senior Vice President at BioDelivery Sciences International, Inc. from 2013 to 2014.
Chief Financial Officer at CeleXx Corp.
Chief Financial Officer at BioVest International, Inc. from 2003 to 2007.
Secretary & Treasurer at Accentia Biopharmaceuticals, Inc. from 2009 to 2013.
Chief Operating & Financial Officer at American Prescription Providers, Inc. from 2000 to 2002.
Chief Financial Officer at TEAMM Pharmaceuticals, Inc. Chief Financial Officer at RetinaPharma Technologies, Inc. Chief Financial Officer at Hopkins Capital Group.
Chief Financial Officer at Telomir Pharmaceuticals, Inc. Chief Executive & Financial Officer at Defender Pharmaceuticals, Inc. Chief Financial Officer at MIRA Pharmaceuticals, Inc. from 2020 to 2023.
Education includes undergraduate degree from the University of South Florida, conferred in 1972.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValutazioneData di valutazione
17/08/2026 1.946.135 ( 1,12% ) 173 206 $ 31/08/2026
10/04/2026 1.512 ( 0,03% ) 3 440 $ 31/08/2026

Posizioni attive di James McNulty

SocietàPosizioneInizio
HEDGEPATH PHARMACEUTICALS INC Direttore Finanziario/CFO 13/12/2022
LUNAI BIOWORKS INC. Direttore/Membro del Consiglio 14/10/2024
Repurposed Therapeutics, Inc.
Direttore Finanziario/CFO -
Corporate Officer/Principal -
Corporate Officer/Principal -
Corporate Officer/Principal -

Precedenti posizioni note di James McNulty

SocietàPosizioneFine
TELOMIR PHARMACEUTICALS, INC. Direttore Finanziario/CFO 01/01/2024
MIRA PHARMACEUTICALS, INC. Direttore Finanziario/CFO 01/04/2023
CV SCIENCES, INC. Direttore/Membro del Consiglio 27/07/2020
░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di James McNulty

Formazione di James McNulty

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

57

Relazioni di 1° grado

25

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private25

Health Technology

Health Technology

Technology Services

Health Technology

Health Technology

Health Technology

Health Technology

Retail Trade

Commercial Services

Distribution Services

Consumer Services

Commercial Services

Distribution Services

Pender, McNulty & Newkirk

Commercial Services

McNulty, Garcia & Ortiz PA

Electronic Technology

Finance

Health Technology

Repurposed Therapeutics, Inc.

Health Technology

Health Technology

Health Technology

Health Technology

  1. Mercati
  2. Insiders
  3. James McNulty
40% di sconto: I migliori strumenti riservati agli abbonati per identificare i migliori investimenti di domani!
g
:
:
ENTRA ORA